Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO)
CUSIP: 87975F104
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, no par value
- Shares outstanding
- 34,382,284
- Total 13F shares
- 2,285,727
- Share change
- -46,337
- Total reported value
- $3,040,166
- Price per share
- $1.33
- Number of holders
- 33
- Value change
- -$68,478
- Number of buys
- 12
- Number of sells
- 13
Quarterly Holders Quick Answers
What is CUSIP 87975F104?
CUSIP 87975F104 identifies TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 87975F104:
Top shareholders of TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Bay Shore Trust |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
5,631,721
mixed-class rows
|
$20,414,715 | — | 21 Nov 2024 | |
| Christopher Chapman MD |
3/4/5
|
CEO & Chairman, Director |
—
class O/S missing
|
975,610
|
$6,048,782 | — | 08 Feb 2024 | |
| MIRA PHARMACEUTICALS, INC. |
3/4/5
|
10%+ Owner |
10%
|
3,521,127
|
$4,823,943 | — | 29 Sep 2025 | |
| John Paul DeJoria |
13D/G
|
John Paul DeJoria, as trustee of the John Paul DeJoria Family Trust, and in his individual capacity |
9.4%
|
3,245,000
|
$4,315,850 | +$1,955,233 | 31 Dec 2025 | |
| Craig Eagle |
3/4/5
|
Director |
—
class O/S missing
|
487,805
|
$3,024,391 | — | 08 Feb 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.2%
|
1,101,752
|
$1,531,435 | — | 30 Sep 2025 | |
| Nathen Fuentes |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
101,134
|
$627,031 | — | 08 Feb 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0.85%
|
291,433
|
$405,092 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.65%
|
222,404
|
$309,142 | — | 30 Sep 2025 | |
| Bradley Kroenig |
3/4/5
|
Director |
—
class O/S missing
|
48,781
|
$302,442 | — | 08 Feb 2024 | |
| Hugh Mccoll III |
3/4/5
|
Director |
—
class O/S missing
|
48,781
|
$302,442 | — | 08 Feb 2024 | |
| Talhia Tuck |
3/4/5
|
Director |
—
class O/S missing
|
48,781
|
$302,442 | — | 08 Feb 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.57%
|
196,030
|
$272,634 | — | 30 Sep 2025 | |
| Michelle Yanez |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
224,391
mixed-class rows
|
$151,224 | — | 27 Aug 2024 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.22%
|
75,340
|
$104,723 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.18%
|
63,536
|
$88,314 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.17%
|
58,600
|
$81,454 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.15%
|
51,454
|
$71,521 | — | 30 Sep 2025 | |
| Suncoast Equity Management |
13F
|
Company |
0.15%
|
51,194
|
$71,160 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.12%
|
41,844
|
$58,163 | — | 30 Sep 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0.07%
|
24,510
|
$32,503 | — | 30 Sep 2025 | |
| OneDigital Investment Advisors LLC |
13F
|
Company |
0.07%
|
23,000
|
$31,970 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.07%
|
22,636
|
$31,464 | — | 30 Sep 2025 | |
| Praetorian Wealth Management, Inc. |
13F
|
Company |
0.06%
|
20,000
|
$27,800 | — | 30 Sep 2025 | |
| Mariner, LLC |
13F
|
Company |
0.06%
|
19,994
|
$27,792 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.06%
|
19,775
|
$27,487 | — | 30 Sep 2025 | |
| Clearstead Advisors, LLC |
13F
|
Company |
0.04%
|
12,530
|
$17,417 | — | 30 Sep 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.03%
|
11,015
|
$15,311 | — | 30 Sep 2025 | |
| KESTRA PRIVATE WEALTH SERVICES, LLC |
13F
|
Company |
0.03%
|
11,000
|
$15,290 | — | 30 Sep 2025 | |
| REGIONS FINANCIAL CORP |
13F
|
Company |
0.03%
|
10,638
|
$14,787 | — | 30 Sep 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
1,251
|
$1,739 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
570
|
$1,000 | — | 30 Sep 2025 | |
| JONES FINANCIAL COMPANIES LLLP |
13F
|
Company |
0%
|
600
|
$834 | — | 30 Sep 2025 | |
| EverSource Wealth Advisors, LLC |
13F
|
Company |
0%
|
379
|
$527 | — | 30 Sep 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
347
|
$482 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
334
|
$464 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
23
|
$32 | — | 30 Sep 2025 | |
| Arax Advisory Partners |
13F
|
Company |
0%
|
9
|
$12 | — | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
4
|
$6 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
2
|
$3 | — | 30 Sep 2025 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
1
|
$1 | — | 30 Sep 2025 | |
| Edward Clouston MacPherson |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
— | — | 27 Aug 2024 | |
| Jerman A. Michael |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
— | — | 27 Aug 2024 | |
| Matthew Paul del Giudice |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
— | — | 27 Aug 2024 | |
| Matthew Pratt Whalen |
3/4/5
|
Director |
—
class O/S missing
|
25,000
|
— | — | 27 Aug 2024 |
Institutional Holders of Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) as of Q4 2025
As of 31 Dec 2025,
Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO) was held by
33 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
2,285,727 shares.
The largest 10 holders included
VANGUARD GROUP INC, BlackRock, Inc., GEODE CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, STATE STREET CORP, Bank of New York Mellon Corp, Suncoast Equity Management, NORTHERN TRUST CORP, XTX Topco Ltd, and World Investment Advisors.
This page lists
33
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
31
Q4 2025 holders
33
Holder diff
2
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.